Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial.
Autorzy:
Huang Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA. Hejazi NS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Biostatistics, T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA. Blette B; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA. Carpp LN; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Benkeser D; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA. Montefiori DC; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA. McDermott AB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Fong Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Janes HE; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Deng W; Moderna, Inc., Cambridge, MA 02139, USA. Zhou H; Moderna, Inc., Cambridge, MA 02139, USA. Houchens CR; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA. Martins K; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA. Jayashankar L; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA. Flach B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Lin BC; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. O'Connell S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. McDanal C; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA. Eaton A; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA. Sarzotti-Kelsoe M; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA. Lu Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Yu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Kenny A; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA. Carone M; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA. Huynh C; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA. Miller J; Moderna, Inc., Cambridge, MA 02139, USA. El Sahly HM; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA. Baden LR; Brigham and Women's Hospital, Boston, MA 02115, USA. Jackson LA; Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA. Campbell TB; Division of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. Clark J; Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. Andrasik MP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA. NeuzilKM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Pajon R; Moderna, Inc., Cambridge, MA 02139, USA. Follmann D; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Donis RO; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA. Koup RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA. On Behalf Of The Immune Assays Moderna Inc Coronavirus Vaccine Prevention Network CoVPN/Coronavirus Efficacy Cove United States Government Usg/CoVPN Biostatistics Teams
Pokaż więcej
Źródło:
Viruses [Viruses] 2023 Sep 29; Vol. 15 (10). Date of Electronic Publication: 2023 Sep 29.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
Characterization of Typhoid Intestinal Perforation in Africa: Results From the Severe Typhoid Fever Surveillance in Africa Program.
Autorzy:
Birkhold M; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA. Datta S; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA. Pak GD; Epidemiology, Public Health, and Impact Unit (EPIC), International Vaccine Institute, Seoul, Republic of Korea. Im J; Epidemiology, Public Health, and Impact Unit (EPIC), International Vaccine Institute, Seoul, Republic of Korea. Ogundoyin OO; Division of Pediatric Surgery, University College Hospital and Department of Surgery, University of Ibadan, Ibadan, Nigeria. Olulana DI; Division of Pediatric Surgery, University College Hospital and Department of Surgery, University of Ibadan, Ibadan, Nigeria. Lawal TA; Division of Pediatric Surgery, University College Hospital and Department of Surgery, University of Ibadan, Ibadan, Nigeria. Afuwape OO; Division of Gastrointestinal Surgery, University College Hospital and Department of Surgery, University of Ibadan, Ibadan, Nigeria. Kehinde A; Department of Medical Microbiology and Parasitology, College of Medicine, University of Ibadan, Ibadan, Nigeria. Phoba MF; Department of Microbiology, Institut National de Recherche Biomedicales, Kinshasa, Democratic Republic of Congo. Nkoji G; Department of Microbiology, Institut National de Recherche Biomedicales, Kinshasa, Democratic Republic of Congo. Aseffa A; Armauer Hansen Research Institute, ALERT Campus, Addis Ababa, Ethiopia. Teferi M; Armauer Hansen Research Institute, ALERT Campus, Addis Ababa, Ethiopia. Yeshitela B; Armauer Hansen Research Institute, ALERT Campus, Addis Ababa, Ethiopia. Popoola O; Department of Community Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria. Owusu M; Department of Medical Diagnostics, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. Nana LRW; Institut Supérieur des Sciences de la Population, Université Joseph Ki Zerbo, Ouagadougou, Burkina Faso. Cakpo EG; Institut Supérieur des Sciences de la Population, Université Joseph Ki Zerbo, Ouagadougou, Burkina Faso. Ouedraogo M; Laboratorie d'Analyses Medicales, Hopital Protestant Schiphra, Ouagadougou, Burkina Faso. Ouangre E; Service de Chirurgie Viscérale, Hopital Yalgado, Ouagadougou, Burkina Faso. Ouedraogo I; Pediatric Department, Hopital Charles de Gaulle, Ouagadougou, Burkina Faso. Heroes AS; Department of Tropical Bacteriology, Institute of Tropical Medicine, Antwerp, Belgium.; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium. Jacobs J; Department of Tropical Bacteriology, Institute of Tropical Medicine, Antwerp, Belgium.; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium. Mogeni OD; Epidemiology, Public Health, and Impact Unit (EPIC), International Vaccine Institute, Seoul, Republic of Korea. Haselbeck A; Epidemiology, Public Health, and Impact Unit (EPIC), International Vaccine Institute, Seoul, Republic of Korea. Sukri L; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA. NeuzilKM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA. Metila OL; Department of Microbiology, Institut National de Recherche Biomedicales, Kinshasa, Democratic Republic of Congo.; Service de Microbiologie, Cliniques Universitaires de Kinshasa, Kinshasa, Democratic Republic of Congo. Owusu-Dabo E; Department of Medical Diagnostics, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. Adu-Sarkodie Y; Department of Medical Diagnostics, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. Bassiahi AS; Institut Supérieur des Sciences de la Population, Université Joseph Ki Zerbo, Ouagadougou, Burkina Faso. Rakotozandrindrainy R; Department of Microbiology and Parasitology, University of Antananarivo, Antananarivo, Madagascar. Okeke IN; Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria. Zellweger RM; Epidemiology, Public Health, and Impact Unit (EPIC), International Vaccine Institute, Seoul, Republic of Korea. Marks F; Epidemiology, Public Health, and Impact Unit (EPIC), International Vaccine Institute, Seoul, Republic of Korea.; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, United Kingdom.; Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany.; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar.
Pokaż więcej
Źródło:
Open forum infectious diseases [Open Forum Infect Dis] 2023 Jun 02; Vol. 10 (Suppl 1), pp. S67-S73. Date of Electronic Publication: 2023 Jun 02 (Print Publication: 2023).
Using Typhoid Conjugate Vaccines to Prevent Disease, Promote Health Equity, and Counter Drug-Resistant Typhoid Fever.
Autorzy:
Nampota-Nkomba N; Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi. Carey ME; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Department of Medicine, University of Cambridge, Cambridge, UK. Jamka LP; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA. Fecteau N; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA. NeuzilKM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Pokaż więcej
Źródło:
Open forum infectious diseases [Open Forum Infect Dis] 2023 Jun 02; Vol. 10 (Suppl 1), pp. S6-S12. Date of Electronic Publication: 2023 Jun 02 (Print Publication: 2023).
Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study.
Autorzy:
Phillips MT; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College St., P.O. Box 208034, New Haven, CT, 06520-8034, USA. Antillon M; Swiss Tropical and Public Health Institute, Basel, Switzerland. Bilcke J; Center for Health Economics Research and Modeling Infectious Diseases, University of Antwerp, Antwerp, Belgium. Bar-Zeev N; International Vaccine Access Center, Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.; Malawi Liverpool Wellcome Programme, Blantyre, Malawi. Limani F; Malawi Liverpool Wellcome Programme, Blantyre, Malawi.; Kamuzu University of Health Sciences, Blantyre, Malawi. Debellut F; Center for Vaccine Innovation and Access, PATH, Geneva, Switzerland. Pecenka C; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA. NeuzilKM; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA. Gordon MA; Malawi Liverpool Wellcome Programme, Blantyre, Malawi.; Kamuzu University of Health Sciences, Blantyre, Malawi.; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK. Thindwa D; Malawi Liverpool Wellcome Programme, Blantyre, Malawi.; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. Paltiel AD; Department of Health Policy, Yale School of Public Health, New Haven, CT, USA. Yaesoubi R; Department of Health Policy, Yale School of Public Health, New Haven, CT, USA. Pitzer VE; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College St., P.O. Box 208034, New Haven, CT, 06520-8034, USA. .
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2023 Mar 08; Vol. 23 (1), pp. 143. Date of Electronic Publication: 2023 Mar 08.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies